New York, NY -- (SBWIRE) -- 01/22/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Netlist, Inc (NASDAQ:NLST), PDL BioPharma Inc (NASDAQ:PDLI), Bridgeline Digital Inc (NASDAQ:BLIN), Pluristem Therapeutics Inc (NASDAQ:PSTI)
Netlist, Inc (NASDAQ:NLST) showed a volume of 2.13 million shares by the end of last trade whereas the average volume of the stock remained 490,183 shares. The stock opened the session at $1.35 but then moved to $1.43. At that price, the stock showed a positive performance of 8.33%. Netlist, Inc. (Netlist) designs, manufactures and sells memory subsystems for datacenter server and high-performance computing and communications markets. Netlist’s memory subsystems consist of combinations of dynamic random access memory integrated circuits (DRAM ICs or DRAM),
Will NLST Continue To Move Higher? Find Out Here
PDL BioPharma Inc (NASDAQ:PDLI) opened the session at $9.10 and closed the session at $9.14. The stock showed a positive performance of 1.90% in previous trading session. Traded with volume of 2.06 million shares in the prior session and the average volume of the stock remained 2.30 million shares. PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies.
For How Long PDLI will fight for Profitability? Read This Trend Analysis report
Bridgeline Digital Inc (NASDAQ:BLIN) opened the session at $1.20 and closed the session at $1.44. The stock showed a positive performance of 21.33% in previous trading session. Traded with volume of 2.06 million shares in the prior session and the average volume of the stock remained 87,850.00 shares. The beta of the stock remained 0.10. Bridgeline Digital, Inc. (Bridgeline) is a developer of a unified Web engagement management product suite named iAPPS and interactive technology solutions that help organizations optimize business processes. Bridgeline’s iAPPS product range provides solutions that integrate Web Content Management, e-commerce,
Why Should Investors Buy BLIN After The Recent Gain? Just Go Here and Find Out
Pluristem Therapeutics Inc (NASDAQ:PSTI) the stock decreased -5.87% and finished the session at $4.17. Traded with volume of 2.05 million shares in the prior session and the average volume of the stock remained 404,491.00 shares. The beta of the stock remained -1.36. Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Will PSTI Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)